The approval process for a Sanofi drug is reportedly facing delays due to the actions of a political appointee. This situation has sparked concerns regarding the influence of politics on regulatory decisions at the FDA.
The issue was highlighted in a recent edition of STAT's D.C. Diagnosis newsletter, which pointed to the potential ramifications of such interference on public health.
As the FDA navigates its role in drug approvals, the involvement of political figures raises questions about the integrity of the process and the prioritization of scientific evidence over political agendas.